MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.010
NaN%
Closed 09:30 02/20 EST
OPEN
--
PREV CLOSE
0.0097
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.014
52 WEEK LOW
0.0070
MARKET CAP
109.84M
P/E (TTM)
-8.4167
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics provides corporate update
TipRanks · 01/30 12:38
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 01/30 06:25
Alterity Sharpens ATH434 Phase 3 Plans as Phase 2 MSA Data Strengthen
TipRanks · 01/30 03:49
Alterity Therapeutics highlights key 2026 objectives
TipRanks · 01/21 12:36
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Barchart · 01/21 06:25
Alterity Therapeutics Advances Lead MSA Drug Toward Phase 3 After Strong Phase 2 Data
TipRanks · 01/21 00:08
Alterity Therapeutics Issues 18 Million Unlisted Options Under Employee Scheme
TipRanks · 01/15 01:33
Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation
TipRanks · 01/13 00:18
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.